AbbVie's Skyrizi hangs Novartis' Cosentyx out to dry in head-to-head psoriasis study
Skyrizi, a key drug in AbbVie’s post-Humira future, has added another feather to its cap.
On Tuesday, the IL-23 inhibitor emerged superior in a head-to-head 327-patient trial against Novartis’ dominant Cosentyx in patients with moderate-to-severe plaque psoriasis.
Data showed Skyrizi induced significantly higher rates of skin clearance compared to Cosentyx, meeting the primary goal of superiority with at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) at week 52. Overall, 87% of Skyrizi-treated patients hit PASI 90, versus 57% of Cosentyx-treated patients at the one year mark.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters